Maturitas最新文献

{"title":"Efficacy and safety of an ultra-low-dose 0.005 % estriol vaginal gel in the prevention of urinary tract infections in postmenopausal women with genitourinary syndrome of menopause: A randomized double-blind placebo-controlled trial","authors":"Nuno Muiños Fernández ,&nbsp;Juan Ignacio Martínez Salamanca ,&nbsp;José Ignacio Pardo González de Quevedo ,&nbsp;M. Pilar Diz Morales ,&nbsp;Lourdes Palomo Alameda ,&nbsp;Susana Duce Tello ,&nbsp;Milagros González Béjar ,&nbsp;Alejandra Rabanal Carrera ,&nbsp;Javier Rosado Martín ,&nbsp;Laura Noguera Vera ,&nbsp;Ana Doyle Sanchez ,&nbsp;Amelia Rodríguez Mariblanca ,&nbsp;Eva García Aguilar","doi":"10.1016/j.maturitas.2024.108128","DOIUrl":"10.1016/j.maturitas.2024.108128","url":null,"abstract":"<div><h3>Objectives</h3><div>This study evaluated the efficacy of an ultra-low-dose 0.005 % estriol vaginal gel in the prevention of urinary tract infections in postmenopausal women with genitourinary syndrome of menopause.</div></div><div><h3>Study design</h3><div>Randomized, double-blind, placebo-controlled, multicenter clinical trial conducted across 28 Spanish sites involving specialists in gynecology, urology, and primary care. A total of 108 postmenopausal women were randomly assigned in a 1:1 ratio to receive 1 g of vaginal gel with 50 micrograms of estriol or an identical moisturizing vaginal gel without estriol.</div></div><div><h3>Main outcome measures</h3><div>The primary outcome was the number of episodes of urinary tract infection by the end of the 24-week treatment. Secondary measures encompassed percentage of patients without recurrence, time to first recurrence, use of antibiotic treatment, vaginal pH, safety, and tolerability, among others.</div></div><div><h3>Results</h3><div>The incidence rate of urinary tract infections (new cases per 100 women-year) was 26 % lower in the group that received estriol vs. the group that received placebo (32.34 vs. 43.76 (RR = 0.74) <em>p</em> &lt; 0.001). The frequency of urinary tract infections fell during treatment in all patients in the estriol group. Favorable pH changes from baseline were observed in the estriol arm at all follow-up visits.</div></div><div><h3>Conclusions</h3><div>Ultra-low-dose 0.005 % estriol vaginal gel is safe and effective in preventing recurrent urinary tract infections in postmenopausal women with genitourinary syndrome of menopause, reducing the incidence and potentially decreasing the susceptibility to urogenital infections by improving vaginal pH.</div><div>Study registration N°: 2018-001481-42. Date of registration: 09-04-2018.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"190 ","pages":"Article 108128"},"PeriodicalIF":3.9,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review and meta-analysis investigating differences in chronic inflammation and adiposity before and after menopause","authors":"Laura E. Pernoud ,&nbsp;Paul A. Gardiner ,&nbsp;Sean D. Fraser ,&nbsp;Kirsten Dillon-Rossiter ,&nbsp;Melinda M. Dean ,&nbsp;Mia A. Schaumberg","doi":"10.1016/j.maturitas.2024.108119","DOIUrl":"10.1016/j.maturitas.2024.108119","url":null,"abstract":"<div><h3>Background</h3><div>Menopause represents a pivotal physiological transition characterized by hormonal fluctuations and an augmented susceptibility to chronic diseases. The relationship between menopause and heightened disease risk may be attributed in part to alterations in low-grade chronic inflammation and adiposity.</div></div><div><h3>Methods</h3><div>Three databases were searched for studies assessing differences in inflammation and body adiposity between pre- and postmenopausal women. Meta-analysis examined the association between menopausal status and key inflammatory biomarkers, including leptin, adiponectin, interleukin-6, tumour necrosis factor-α and c-reactive protein, and indices of body adiposity (fat mass, waist circumference, waist-to-hip-ratio and body mass index). The National Institute of Health Quality Assessment Tool for Observational and Cross-sectional studies was used to evaluate quality of studies, and GRADE-assessed evidence certainty.</div></div><div><h3>Results</h3><div>Levels of adiponectin and leptin were higher in postmenopausal women than in premenopausal women [(1.30 μg/ml, 95 % CI; 0.56 to 2.03 μg/ml, <em>p</em> = 0.001), (0.88 ng/ml; 95 % CI: 0.22 to 1.52; <em>p</em> = 0.008)]. A trend towards significance was observed for tumour necrosis factor-α (0.59 pg/ml, 95 % CI; −0.07 to 1.26 pg/ml, <em>p</em> = 0.080), with no significant differences in interleukin-6 and c-reactive protein [(0.83 pg/ml, 95 % CI; −0.24 to 1.91 pg/ml, <em>p</em> = 0.128), (0.06 mg/ml, 95 % CI; −0.17 to 0.29, <em>p</em> = 0.606)]. Postmenopausal women had greater waist circumference, waist-to-hip-ratio and body mass index than premenopausal women [(0.74 cm; 95 % CI: 1.02 to 0.47; <em>p</em> ≤0.001), (0.78; 95 % CI: 1.47 to −0.09; <em>p</em> = 0.027), (0.31 kg/m²; 95 % CI: 0.50 to 0.12; <em>p</em> = 0.001)].</div></div><div><h3>Conclusions</h3><div>Postmenopausal women had higher adipokine levels and greater adiposity. However, given the low certainty of the available evidence, future prospective cohort studies assessing inflammatory changes over the menopausal transition are warranted to inform future clinical decisions. Protocol registered on the Open Science Framework (OSF-ID: <span><span>10.17605/OSF.IO/DY8T6</span><svg><path></path></svg></span>).</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"190 ","pages":"Article 108119"},"PeriodicalIF":3.9,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142322098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Menopause and endometriosis","authors":"Chiara Cassani ,&nbsp;Sara Tedeschi ,&nbsp;Laura Cucinella ,&nbsp;Vittoria Morteo ,&nbsp;Cristina Angela Camnasio ,&nbsp;Lara Tiranini ,&nbsp;Ellis Martini ,&nbsp;Rossella E. Nappi","doi":"10.1016/j.maturitas.2024.108129","DOIUrl":"10.1016/j.maturitas.2024.108129","url":null,"abstract":"<div><div>The shift in paradigm from the belief that endometriosis exclusively affects women of reproductive age has brought attention to its manifestation in postmenopausal patients. Despite this emerging awareness, there remains a dearth of information in the literature regarding postmenopausal endometriosis, with uncertainties surrounding its prevalence, clinical significance, optimal management strategies, and prognosis. Clinical manifestations of endometriosis in menopausal patients lack specificity, with pain onset possible at any stage of life. The primary approach for symptomatic postmenopausal endometriosis continues to be surgical excision, serving both diagnostic and therapeutic purposes while mitigating the risk of coexisting malignancies. Managing the disease in postmenopausal women presents challenges due to possible contraindications for menopausal hormone therapy and the elevated risk of recurrence and malignant transformation. However, conclusive data regarding the appropriateness of menopausal hormone therapy in women with endometriosis or a history of the disease are lacking. Current recommendations lean towards prioritizing combined menopausal hormone therapy formulations or tibolone over estrogen-only therapies due to their potentially higher malignancy risk. The possible increased risk of osteoporosis and cardiovascular disease in postmenopausal women with endometriosis is likely linked to a history of surgical menopause at an earlier age, but more research is warranted. This narrative review summarizes the available literature and provides insights into the intricate connection between endometriosis and menopause, shedding light on pathogenesis, symptoms, oncologic risk, diagnosis, and treatment.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"190 ","pages":"Article 108129"},"PeriodicalIF":3.9,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142359053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective and harmful social and psychological factors associated with mood and anxiety disorders in perimenopausal women: A narrative review","authors":"Kayla McElhany ,&nbsp;Seema Aggarwal ,&nbsp;Geri Wood ,&nbsp;Jennifer Beauchamp","doi":"10.1016/j.maturitas.2024.108118","DOIUrl":"10.1016/j.maturitas.2024.108118","url":null,"abstract":"<div><div>Perimenopause is often called a window of vulnerability for the development or exacerbation of mood and anxiety disorders. Evidence points to social and psychological factors contributing to the onset of mood and anxiety disorders or the symptoms of depression and anxiety during perimenopause. Therefore, the purpose of this narrative review was to synthesize the findings of studies examining associations between social and psychological factors and the development of mood and anxiety disorders and the symptoms of depression and anxiety during perimenopause. PsychINFO, Ovid MEDLINE, and CINAHL were searched for studies (published between January 2014 and November 2023) assessing the social and psychological factors associated with perimenopausal mood and anxiety disorders and the symptoms of depression and anxiety. These factors were categorized as either protective or harmful. Study quality was assessed using STROBE guidelines. The search yielded 17 studies. Social support was identified as a social factor protective against perimenopausal depression and anxiety. Resiliency characteristics were reported to be protective psychological factors associated with fewer depressive symptoms. Mental health history, family history of major depressive disorder, trait anxiety and neuroticism, stressful life events, adverse childhood events, and chronic stress were categorized as harmful psychological factors associated with depression during perimenopause. Limited research has been conducted to understand factors associated with perimenopausal anxiety. The identification of these social and psychological factors associated with mood and anxiety disorders during perimenopause will help lead to earlier detection of women at risk and the development of multifaceted interventions.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"190 ","pages":"Article 108118"},"PeriodicalIF":3.9,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic population","authors":"John C. Stevenson ,&nbsp;Mulan Ren ,&nbsp;Elke Kahler ,&nbsp;Marcelo Graziano Custodio ,&nbsp;Rossella Elena Nappi ,&nbsp;Tetiana Tatarchuk ,&nbsp;Tommaso Simoncini ,&nbsp;Viktoriya Karpova ,&nbsp;Qi Yu","doi":"10.1016/j.maturitas.2024.108117","DOIUrl":"10.1016/j.maturitas.2024.108117","url":null,"abstract":"<div><h3>Objectives</h3><div>Evidence suggests ethnicity-specific differences in postmenopausal symptoms, highlighting the need for therapies that are efficacious across different ethnicities. We evaluated the efficacy of an ultra-low dose combination of 0.5 mg estradiol and 0.25 mg dydrogesterone (E 0.5 mg/D 2.5 mg) in alleviating vasomotor symptoms across a multi-ethnic population.</div></div><div><h3>Study design</h3><div>Data from two controlled trials were pooled to form a dataset of 583 postmenopausal women from across Europe and China. Participants were randomized to receive treatment with E 0.5 mg/D 2.5 mg or placebo for 12 weeks.</div></div><div><h3>Main outcome measures</h3><div>The main efficacy variable was absolute change in the number of hot flushes from baseline to end of treatment. Health-related quality of life and safety were also assessed.</div></div><div><h3>Results</h3><div>Change in the number of hot flushes per day was greater with E 0.5 mg/D 2.5 mg <em>versus</em> placebo (mean difference − 1.5, 95 % confidence interval − 2.1, −1.0; <em>p</em> &lt; 0.001). Participants treated with E 0.5 mg/D 2.5 mg reported improvement in health-related quality of life (including psychological symptoms, vaginal dryness), and high amenorrhea rates. Combined E 0.5 mg/D 2.5 mg was well tolerated: there were no differences between groups in the percentage of participants with at least one serious adverse event or treatment-emergent serious adverse events. Analysis of change in body weight indicated no differences between groups.</div></div><div><h3>Conclusions</h3><div>This pooled analysis demonstrates the consistent efficacy of E 0.5 mg/D 2.5 mg in the treatment of menopause-related symptoms across a multi-ethnic population of postmenopausal women.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"190 ","pages":"Article 108117"},"PeriodicalIF":3.9,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0378512224002123/pdfft?md5=bb23181ffbbca67c7fb3a3dc900e4a8a&pid=1-s2.0-S0378512224002123-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in the predictors of skeletal muscle microvascular reactivity in older individuals","authors":"Thiago Silveira Alvares ,&nbsp;Felipe Mattioni Maturana ,&nbsp;Rogerio Nogueira Soares","doi":"10.1016/j.maturitas.2024.108115","DOIUrl":"10.1016/j.maturitas.2024.108115","url":null,"abstract":"<div><p>Aging is associated with an increased risk of cardiovascular disease and vascular dysfunction. Reduced nitric oxide bioavailability is considered one of the key mechanisms underlying vascular dysfunction in large arteries of older adults. However, the relationship between cardiovascular disease risk factors, nitric oxide bioavailability, and skeletal muscle microvascular reactivity, an early hallmark in cardiovascular disease progression, is unclear in older individuals. Also uncertain is whether this relationship is influenced by sex. Therefore, this study assessed the association between cardiovascular disease risk factors, circulating markers of nitric oxide availability (plasma nitrate and nitrite), and skeletal muscle microvascular reactivity in older individuals. First, we confirmed in a cohort of young and older individuals that aging is associated with skeletal muscle microvascular dysfunction. Next, we observed that skeletal muscle microvascular reactivity (<em>P</em> = 0.653; η² = 0.016) and circulating nitric oxide metabolites (Nitrate: <em>P</em> = 0.641, η² = 0.011; Nitrite: <em>P</em> = 0.560, η² = 0.017; NOx: <em>P</em> = 0.639, η² = 0.011) did not differ between older males and females. Finally, using multivariate regression models, we found that: (i) the number of cardiovascular risk factors was negatively associated with skeletal muscle microvascular reactivity in older males and females (B = −0.132, <em>P</em> = 0.044); (ii) the relationship between plasma nitrite and skeletal muscle microvascular reactivity was influenced by sex (F = 6.837, <em>P</em> = 0.016); and (iii) skeletal muscle microvascular reactivity in older females displayed a strong positive association with plasma nitrite (R² = 0.720, <em>P</em> &lt; 0.001). While the impact of cardiovascular disease risk factors on skeletal muscle microvascular reactivity was not influenced by sex, sex-related discrepancies were found in the relationship between nitric oxide bioavailability and skeletal muscle microvascular reactivity in older individuals.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"189 ","pages":"Article 108115"},"PeriodicalIF":3.9,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142229171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Better understanding fall risk: AI-based computer vision for contextual gait assessment","authors":"Jason Moore ,&nbsp;Peter McMeekin ,&nbsp;Samuel Stuart ,&nbsp;Rosie Morris ,&nbsp;Yunus Celik ,&nbsp;Richard Walker ,&nbsp;Victoria Hetherington ,&nbsp;Alan Godfrey","doi":"10.1016/j.maturitas.2024.108116","DOIUrl":"10.1016/j.maturitas.2024.108116","url":null,"abstract":"<div><p>Contemporary research to better understand free-living fall risk assessment in Parkinson's disease (PD) often relies on the use of wearable inertial-based measurement units (IMUs) to quantify useful temporal and spatial gait characteristics (e.g., step time, step length). Although use of IMUs is useful to understand some intrinsic PD fall-risk factors, their use alone is limited as they do not provide information on extrinsic factors (e.g., obstacles). Here, we update on the use of ergonomic wearable video-based eye-tracking glasses coupled with AI-based computer vision methodologies to provide information efficiently and ethically in free-living home-based environments to better understand IMU-based data in a small group of people with PD. The use of video and AI within PD research can be seen as an evolutionary step to improve methods to understand fall risk more comprehensively.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"189 ","pages":"Article 108116"},"PeriodicalIF":3.9,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0378512224002111/pdfft?md5=91997a03b833ea6d9eb7459bd0cdee2b&pid=1-s2.0-S0378512224002111-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142232620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and impact of vasomotor symptoms associated with menopause among women in Brazil: Subgroup analysis from an international cross-sectional survey","authors":"Rogério Bonassi Machado ,&nbsp;Roberto Soler ,&nbsp;Marcos Freire ,&nbsp;Maria Celeste Osorio Wender ,&nbsp;Luciano Melo Pompei","doi":"10.1016/j.maturitas.2024.108114","DOIUrl":"10.1016/j.maturitas.2024.108114","url":null,"abstract":"<div><h3>Objective</h3><div>This study assessed the prevalence and impact of moderate and/or severe vasomotor symptoms and related treatment patterns in midlife women in Brazil.</div></div><div><h3>Study design</h3><div>Brazilian women aged 40 to 65 years completed an online survey. The prevalence of moderate to severe vasomotor symptoms was assessed in postmenopausal women who completed a series of questionnaires to elicit responses regarding their treatment patterns and attitudes to treatments.</div></div><div><h3>Main outcome measures</h3><div>Perimenopausal and postmenopausal women with moderate to severe vasomotor symptoms completed three standardized questionnaires (Menopause-Specific Quality of Life questionnaire, Work Productivity and Activity Impairment questionnaire, and the Patient-Reported Outcomes Measurement Information System Sleep Disturbances Short Form 8b) and answered open-ended questions.</div></div><div><h3>Results</h3><div>Of 1244 postmenopausal women who accessed the survey, 36.2 % had experienced moderate to severe vasomotor symptoms in the previous month. Moderate to severe vasomotor symptoms among 501 perimenopausal and postmenopausal women negatively affected overall quality of life (mean total score on the Menopause-Specific Quality of Life questionnaire was 3.6/8). On the Work Productivity and Activity Impairment questionnaire, women's scores for impairments in overall work and daily activities due to vasomotor symptoms were 50.3 % and 60.0 %, respectively. Overall mean (standard deviation) score on the Patient-Reported Outcomes Measurement Information System Sleep Disturbances Short Form 8b was 25.5 (5.8) on a scale of 8 to 40. Most women sought medical advice (65.5 %), but over half were not receiving treatment. Those who received treatment reported moderately favorable attitudes to hormone and nonhormone prescription medicines, but safety concerns remained.</div></div><div><h3>Conclusion</h3><div>Brazilian women experienced a relatively high prevalence and burden of moderate to severe vasomotor symptoms.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"189 ","pages":"Article 108114"},"PeriodicalIF":3.9,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0378512224002093/pdfft?md5=32337338e45360cab7520722b2a513ae&pid=1-s2.0-S0378512224002093-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the efficacy of a personalized information-provision and exercise-coaching app on the quality of life of menopausal women","authors":"Na Yeon Kim ,&nbsp;Da Seul Kim ,&nbsp;Doug Hyun Han ,&nbsp;Ji Sun Hong ,&nbsp;Yoojin Shim ,&nbsp;Youn Jung Yoon ,&nbsp;Hee Jun Kim ,&nbsp;Sun Mi Kim","doi":"10.1016/j.maturitas.2024.108113","DOIUrl":"10.1016/j.maturitas.2024.108113","url":null,"abstract":"<div><h3>Objectives</h3><p>Menopausal symptoms severely impact women's quality of life (QoL). Digital health interventions provide an accessible, personalized alternative for managing menopausal symptoms. In this study, we validated the Menopause Assistant Manager (MAMA®; Hudit, Seoul, S. Korea) app developed to provide personalized information, exercise coaching, and management of appointments and medications to menopausal women, and evaluated its efficacy on their QoL.</p></div><div><h3>Study design</h3><p>This nonrandomized interventional trial enrolled 48 peri- and postmenopausal women into experimental (MAMA) and control (Waitlist) groups (<em>n</em> = 24 each). Participants in the MAMA group used the app for 8 weeks, whereas the Waitlist group received no intervention. Both groups continued their usual treatments.</p></div><div><h3>Main outcome measures</h3><p>Clinical assessments at baseline and study completion included the World Health Organization Quality of Life Brief Version (WHOQOL-BREF), Menopause Rating Scale, Patient Health Questionnaire-9, Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-15 (PHQ-15), Menopause Emotional Symptom Questionnaire, and Subjective Memory Complaints Questionnaire.</p></div><div><h3>Results</h3><p>Compared with the Waitlist group, the MAMA group showed postintervention improvements in WHOQOL-BREF physical health (F = 4.84, <em>P</em> = .03) and environmental (F = 5.01, <em>P</em> = .03) domains and GAD-7 (F = 5.53, <em>P</em> = .02) and PHQ-15 (F = 4.14, <em>P</em> = .048) scores. Changes in WHOQOL-BREF physical health scores negatively correlated with PHQ-15 scores (ρ = −0.53, <em>P</em> = .004).</p></div><div><h3>Conclusion</h3><p>By increasing treatment accessibility, the app improved physical and environmental QoL and reduced anxiety and somatic symptoms. App-based exercise coaching alleviated somatic symptoms, and the in-app psychological content reduced anxiety by normalizing menopausal symptoms, providing accurate information, decreasing uncertainty, and improving symptom perception.</p></div><div><h3>Trial registration</h3><p>Clinical Research Information Service KCT 0008603; <span><span>https://cris.nih.go.kr/cris/search/detailSearch.do?seq=25078&amp;status=5&amp;seq_group=25078&amp;search_page=M</span><svg><path></path></svg></span>.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"189 ","pages":"Article 108113"},"PeriodicalIF":3.9,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142229172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prior pre-eclampsia does not diminish the vascular protective effect of menopausal hormone therapy","authors":"Minttu Venetkoski ,&nbsp;Hanna Savolainen-Peltonen ,&nbsp;Johanna M. Joensuu ,&nbsp;Mika Gissler ,&nbsp;Olavi Ylikorkala ,&nbsp;Tomi S. Mikkola","doi":"10.1016/j.maturitas.2024.108112","DOIUrl":"10.1016/j.maturitas.2024.108112","url":null,"abstract":"<div><h3>Objective</h3><p>Women with prior pre-eclampsia are at increased risk of cardiovascular disease (CVD). Menopausal hormone therapy (MHT) may affect this risk. We evaluated the impact of MHT use on cardiovascular risk between women with and without prior pre-eclampsia.</p></div><div><h3>Study design and main outcome measures</h3><p>We assessed the occurrence of any CVD, myocardial infarction (MI) and stroke in MHT users (<em>n</em> = 9700) and non-users (<em>n</em> = 19,914) with prior pre-eclampsia, and likewise in MHT users (<em>n</em> = 27,764) and non-users (<em>n</em> = 58,248) without prior pre-eclampsia over the period 1994–2019. Follow-up started at MHT initiation (mean age 50.4 in pre-eclamptic women and 50.3 in non-pre-eclamptic women) and lasted for a mean of 13.3 years.</p></div><div><h3>Results</h3><p>The use of MHT in prior pre-eclamptic women was associated with significant risk reductions for any CVD (HR 0.85, 95 % CI 0.78–0.91), MI (HR 0.66, 95 % CI 0.55–0.78) and stroke events (HR 0.71, 95 % CI 0.63–0.81) in comparison with non-users with prior pre-eclampsia. The risk reductions for cardiovascular deaths were even more pronounced (HR 0.43, 95 % CI 0.31–0.59 for any CVD death; HR 0.49, 95 % CI 0.30–0.80 for MI death; HR 0.25, 95 % CI 0.10–0.64 for stroke death). However, none of these risk reductions differed from those seen in MHT users without prior pre-eclampsia. The risk of any CVD decreased already within five years of MHT use in women with prior pre-eclampsia but not in those without prior pre-eclampsia.</p></div><div><h3>Conclusions</h3><p>The use of MHT is associated with reduced CVD risk in women with prior pre-eclampsia. This is important to clinicians considering the initiation of MHT for recently menopausal women with prior pre-eclampsia.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"189 ","pages":"Article 108112"},"PeriodicalIF":3.9,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S037851222400207X/pdfft?md5=197aecea370a2ae98a580f8c545fcbbe&pid=1-s2.0-S037851222400207X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142151644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}